TD Cowen on Verrica Pharmaceuticals (VRCA): 'We are encouraged by the increased Ycanth prescribing in lieu of compounded cantharidin'
Tweet Send to a Friend
TD Cowen analyst Stacy Ku reiterated a Buy rating and $20.00 price target on Verrica Pharmaceuticals (NASDAQ: VRCA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
